GT Biopharma is trading at $6.54, up 7.21%, with no specific cause for the gain established.
- No clear company-specific catalyst for October 5 was identified, and the supplied market picture is mixed.
- The latest company press release shown is dated September 15 and concerns FDA clearance of an investigational new drug application for GTB-5550 in multiple myeloma; it is not a new October 5 announcement.
- Trading volume was not available in the reviewed source.